Fireside Chat, Interview
Pande & Conde on: Players and Paths for Healthcare Startups
- The healthcare technology sector is characterized by significant complexity, requiring navigation of a multi-step chronology that spans discovery, regulatory approval, reimbursement, system education, and patient adoption.
- Diagnostic tools developed via Laboratory-Derived Tests (LDT) in CLIA labs are projected to offer a lower-risk pathway to market with faster timelines compared to the significantly more difficult and lengthy therapeutic development process involving animal testing and Phase One through Three clinical trials.
- The U.S. R&D sector is identified as a $75 billion annual industry, presenting an attractive market for selling tools where success relies on transformative, widely applicable technology that commands a fraction of this spend without excluding other partners.
- Strategic market entry is contingent on specific technology types, with broadly applicable diagnostics favoring LDT paths, platforms for novel drug development potentially requiring a shift to becoming a drug company, and deep domain disease expertise platforms leaning toward partnership models.
- Entrepreneurial execution success depends on defining go-to-market issues from the outset, specifically understanding validation requirements, approval processes, and payment structures to determine whether to develop proprietary assets or empower industry players.
- Companies like Atomab are expected to pursue a partnership model with virtually every therapy developer, securing upfront payments while retaining a significant share of downstream economics once efficacy is proven.
- The landscape for full genome sequencing at scale has transitioned from being viewed as impossible to necessary, with Illumina positioned as an essential entity in this shift.
- Atomab remains a private company valued well north of one billion dollars as of the last known update.